肾移植患者感染COVID-19引起他克莫司血药浓度升高1例  

Infection with COVID-19 in kidney transplant recipient with an elevated level of tacrolimus:one case report

作　　者：邵佳[1,2] 陈凡[1] 任海霞[1] SHAO Jia;CHEN Fan;REN Haixia(Depart-ment of Pharmacy,Tianjin First Central Municipal Hospital,Tianjin 300192,China;National Health Commission’s Key Laboratory of Critical Care Medicine,Tianjin First Central Municipal Hospital,Tianjin 300192,China)

机构地区：[1]天津市第一中心医院药学部,天津300192 [2]天津市第一中心医院国家卫生健康委员会危重病急救医学重点实验室,天津300192

出　　处：《中国医院药学杂志》2024年第16期1960-1962,共3页Chinese Journal of Hospital Pharmacy

摘　　要：肾移植患者长期使用免疫抑制剂,其感染COVID-19的风险增加。该例报告中,肾移植患者长期使用他克莫司(tacrolimus,TAC)预防排斥反应,感染COVID-19引起TAC血药浓度异常升高。通过文献复习,对造成TAC血药浓度升高的病理因素以及因TAC血药浓度升高导致的肝损伤、肾损伤等不良反应进行分析,为今后感染COVID-19的肾移植患者病理因素分析,以及TAC血药浓度异常引起的不良反应防治提供参考。An elevated risk of COVID-19 is due to longterm use of immunosuppressants in kidney transplant(KT)recipients.In this report,one patient received tacrolimus(TAC)for a long time to prevent rejection.And COVID-19 caused an abnormal blood drug concentration of TAC.Patho⁃logical factors and adverse heptorenal reactions leading to an elevated level of TAC were examined through a literature review.It provided references for analyzing pathological fac⁃tors in COVID-19 KT recipients and preventing adverse reac⁃tions of an abnormal blood concentration of TAC.

关 键 词：肾移植 他克莫司 COVID-19 

分 类 号：R979.5[医药卫生—药品]